%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Abraham R. Oduro, Seth Owusu-Agyei, Margaret Gyapong, Isaac Osei, Alex Adjei, Abena Yawson, Edward Sobe, Rita Baiden, Martin Adjuik, Fred Binka
Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 14 0 R/Contents 15 0 R/TrimBox[0 0 612 792]>>
endobj
14 0 obj
[16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R 32 0 R 33 0 R]
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref001)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref002)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref003)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref003)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref004)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref005)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref007)>>
endobj
23 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref008)>>
endobj
24 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref009)>>
endobj
25 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref008)>>
endobj
26 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref010)>>
endobj
27 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref011)>>
endobj
28 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref011)>>
endobj
29 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref012)>>
endobj
30 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref013)>>
endobj
31 0 obj
<>/Border[0 0 0]/A 34 0 R>>
endobj
34 0 obj
<>
endobj
32 0 obj
<>/Border[0 0 0]/A 35 0 R>>
endobj
35 0 obj
<>
endobj
33 0 obj
<>/Border[0 0 0]/A 36 0 R>>
endobj
36 0 obj
<>
endobj
15 0 obj
[37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R 44 0 R 45 0 R 46 0 R 47 0 R 48 0 R 49 0 R 50 0 R]
endobj
37 0 obj
<>stream
q
0.45 0.36 0.35 0.01 k
0 w
575.9997 533.6144 m
199.9998 533.6144 l
199.9998 534.1144 l
575.9997 534.1144 l
f*
0.83 0.64 0.02 0 k
338.8535 445.9465 m
343.6157 445.9465 l
h
f*
348.0945 445.9465 m
352.8567 445.9465 l
h
f*
266.2866 393.9024 m
271.0488 393.9024 l
h
f*
301.3228 367.937 m
306.085 367.937 l
h
f*
310.5638 367.937 m
315.326 367.937 l
h
f*
221.726 289.9276 m
226.4882 289.9276 l
h
f*
231.6472 289.9276 m
236.4094 289.9276 l
h
f*
452.8063 276.9449 m
457.5685 276.9449 l
h
f*
462.0472 276.9449 m
466.8094 276.9449 l
h
f*
351.4394 250.9228 m
356.2016 250.9228 l
h
f*
361.3606 250.9228 m
370.885 250.9228 l
h
f*
545.2157 211.9181 m
554.6835 211.9181 l
h
f*
300.2457 185.8961 m
309.7701 185.8961 l
h
f*
378.1417 107.9433 m
387.6661 107.9433 l
h
f*
422.8157 81.9213 m
432.3402 81.9213 l
h
f*
0 g
1 j
1 J
9.5 0 0 9.5 200.0125 707.7543 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(infections)Tj
4.3921 0 Td
(\(4.6%\),)Tj
3.4135 0 Td
(gastrointestinal)Tj
6.8628 0 Td
(disorders)Tj
4.2789 0 Td
(\(1.0%\))Tj
3.1389 0 Td
(and)Tj
1.8679 0 Td
(local)Tj
2.2439 0 Td
(reactions)Tj
4.2251 0 Td
(at)Tj
1.0503 0 Td
(the)Tj
1.5933 0 Td
(site)Tj
1.7545 0 Td
(of)Tj
1.0503 0 Td
(vene-)Tj
-35.8715 -1.474 Td
(section)Tj
3.3478 0 Td
(\(0.5%\).)Tj
3.4195 0 Td
(Others)Tj
3.1986 0 Td
(were)Tj
2.3632 0 Td
(respiratory)Tj
4.8875 0 Td
(disorders)Tj
4.2788 0 Td
(\(0.4%\))Tj
3.139 0 Td
(and)Tj
1.8679 0 Td
(nervous)Tj
3.7358 0 Td
(system)Tj
3.3657 0 Td
(disorders)Tj
-33.6038 -1.474 Td
(\(0.3%\).)Tj
3.4134 0 Td
(There)Tj
2.8048 0 Td
(were)Tj
2.3632 0 Td
(nine)Tj
2.0828 0 Td
(adverse)Tj
3.7357 0 Td
(events)Tj
3.139 0 Td
(of)Tj
1.0443 0 Td
(special)Tj
3.2882 0 Td
(interest)Tj
3.4612 0 Td
(\(AESI\);)Tj
3.4255 0 Td
(itching/pruritus)Tj
6.642 0 Td
(\(7\),)Tj
1.7067 0 Td
(dizzi-)Tj
-37.1068 -1.474 Td
(ness)Tj
2.3094 0 Td
(\(1\),)Tj
1.7068 0 Td
(and)Tj
1.8619 0 Td
(skin)Tj
1.9813 0 Td
(lesions)Tj
3.2881 0 Td
(\(1\).)Tj
1.7068 0 Td
(Patients)Tj
3.7954 0 Td
(who)Tj
2.029 0 Td
(took)Tj
2.0947 0 Td
(medications)Tj
5.4962 0 Td
(prior)Tj
2.1901 0 Td
(to)Tj
1.0443 0 Td
(enrolment)Tj
4.619 0 Td
(had)Tj
1.8619 0 Td
(higher)Tj
-35.9849 -1.474 Td
(incidence)Tj
4.3802 0 Td
(of)Tj
1.0384 0 Td
(AEs)Tj
2.035 0 Td
(compared)Tj
4.6129 0 Td
(with)Tj
1.9634 0 Td
(those)Tj
2.6377 0 Td
(without)Tj
3.3419 0 Td
(\(9.3%)Tj
2.7988 0 Td
(vs.)Tj
1.48 0 Td
(6.1%;)Tj
2.7511 0 Td
(P)Tj
/F5 1 Tf
[( )]TJ
/F0 1 Tf
(0.001\).)Tj
4.5354 0 Td
(Statistically)Tj
5.1501 0 Td
(signifi-)Tj
-36.7249 -1.474 Td
(cant)Tj
2.0886 0 Td
(associations)Tj
5.6574 0 Td
(were)Tj
2.3632 0 Td
(found)Tj
2.6914 0 Td
(between)Tj
3.9565 0 Td
(the)Tj
1.5994 0 Td
(reported)Tj
3.8968 0 Td
(AEs)Tj
2.0469 0 Td
(and)Tj
1.862 0 Td
(age)Tj
1.8678 0 Td
(of)Tj
1.0444 0 Td
(patients)Tj
3.682 0 Td
(\(P)Tj
/F5 1 Tf
[( )]TJ
/F0 1 Tf
(0.001\),)Tj
4.8756 0 Td
(their)Tj
-37.632 -1.474 Td
(body)Tj
2.3631 0 Td
(mass)Tj
2.59 0 Td
(index)Tj
2.578 0 Td
(\(BMI\))Tj
2.6497 0 Td
(\(P)Tj
/F5 1 Tf
[( )]TJ
/F0 1 Tf
1.7962 0 Td
(0.001\))Tj
3.0197 0 Td
(and)Tj
1.8678 0 Td
(parasite)Tj
3.7298 0 Td
(densities)Tj
4.1177 0 Td
(\(P)Tj
/F5 1 Tf
[( )]TJ
/F0 1 Tf
1.7903 0 Td
(0.001\).)Tj
ET
Q
q
1 j
1 J
0 w
11.4998 0 0 11.4998 200.0125 592.1007 cm
BT
/F2 1 Tf
1 TL
-0.0035 Tc
0 0 Td
(Conclusion)Tj
ET
Q
q
1 j
1 J
0 w
9.5 0 0 9.5 200.0125 575.0929 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(Dihydroartemisinin-Pip)Tj
9.9301 0 Td
(eraquine)Tj
4.058 0 Td
(was)Tj
1.9813 0 Td
(well)Tj
1.9156 0 Td
(tolerated)Tj
4.064 0 Td
(with)Tj
1.9753 0 Td
(no)Tj
1.3188 0 Td
(serious)Tj
3.4016 0 Td
(safety)Tj
2.8645 0 Td
(concerns)Tj
4.237 0 Td
(identi-)Tj
-35.7462 -1.474 Td
(fied.)Tj
2.0886 0 Td
(Obesity)Tj
3.5806 0 Td
(and)Tj
1.8619 0 Td
(prior)Tj
2.1961 0 Td
(enrolment)Tj
4.613 0 Td
(medication)Tj
5.0009 0 Td
(were)Tj
2.3572 0 Td
(among)Tj
3.2464 0 Td
(significant)Tj
4.6071 0 Td
(factors)Tj
3.1986 0 Td
(associated)Tj
4.9472 0 Td
(with)Tj
-37.6976 -1.474 Td
(increased)Tj
4.4996 0 Td
(AEs)Tj
2.0409 0 Td
(reporting.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 477.0141 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 460.0062 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Systematic)Tj
4.473 0 Td
(clinical)Tj
3.0784 0 Td
(studies)Tj
2.9877 0 Td
(in)Tj
1.0318 0 Td
(human)Tj
3.0784 0 Td
(volunteers)Tj
4.3823 0 Td
(are)Tj
1.4514 0 Td
(often)Tj
2.2847 0 Td
(carried)Tj
3.0387 0 Td
(out)Tj
1.5534 0 Td
(in)Tj
1.0318 0 Td
(order)Tj
2.4208 0 Td
(to)Tj
1.0261 0 Td
(discover)Tj
3.5546 0 Td
(the)Tj
-35.3931 -1.2982 Td
(effects)Tj
2.7269 0 Td
(of)Tj
1.0148 0 Td
(new)Tj
1.8765 0 Td
(medicinal)Tj
4.1726 0 Td
(products)Tj
3.7587 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.2585 0 Td
(2)Tj
0 g
(].)Tj
1.2586 0 Td
(Sometimes,)Tj
4.8416 0 Td
(these)Tj
2.2563 0 Td
(new)Tj
1.8766 0 Td
(medicinal)Tj
4.1782 0 Td
(products)Tj
3.753 0 Td
(are)Tj
1.4457 0 Td
(devel-)Tj
-34.418 -1.3039 Td
(oped)Tj
2.194 0 Td
(and)Tj
1.7291 0 Td
(introduced)Tj
4.6431 0 Td
(in)Tj
1.0375 0 Td
(populations)Tj
4.9492 0 Td
(on)Tj
1.2756 0 Td
(the)Tj
1.4683 0 Td
(premise)Tj
3.4073 0 Td
(that)Tj
1.7744 0 Td
(the)Tj
1.4741 0 Td
(individual)Tj
4.2859 0 Td
(and)Tj
1.7291 0 Td
(community)Tj
4.8869 0 Td
(bene-)Tj
-34.8545 -1.2983 Td
(fits)Tj
1.4343 0 Td
(justify)Tj
2.6702 0 Td
(it.)Tj
1.0148 0 Td
(However,)Tj
4.0762 0 Td
(uncommon)Tj
4.9209 0 Td
(and)Tj
1.7291 0 Td
(rare)Tj
1.8199 0 Td
(adverse)Tj
3.2144 0 Td
(events)Tj
2.7326 0 Td
(\(AEs\))Tj
2.5115 0 Td
(with)Tj
2.0012 0 Td
(delayed)Tj
3.2542 0 Td
(onset)Tj
2.3584 0 Td
(are)Tj
-33.7377 -1.2983 Td
(usually)Tj
3.016 0 Td
(not)Tj
1.576 0 Td
(detected)Tj
3.566 0 Td
(before)Tj
2.7383 0 Td
(such)Tj
2.0579 0 Td
(new)Tj
1.8765 0 Td
(products)Tj
3.7531 0 Td
(are)Tj
1.4513 0 Td
(deployed)Tj
3.8494 0 Td
(into)Tj
1.8369 0 Td
(the)Tj
1.474 0 Td
(general)Tj
3.1294 0 Td
(population)Tj
4.5921 0 Td
(for)Tj
-34.9169 -1.3039 Td
(widespread)Tj
4.7565 0 Td
(use)Tj
1.5307 0 Td
([)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(].)Tj
1.6044 0 Td
(Significant)Tj
4.5013 0 Td
(subpopulations)Tj
6.3439 0 Td
(with)Tj
2.0013 0 Td
(underlying)Tj
4.5978 0 Td
(medical)Tj
3.3618 0 Td
(conditions)Tj
4.4787 0 Td
(are)Tj
1.4457 0 Td
(often)Tj
-34.6221 -1.2982 Td
(excluded)Tj
3.7813 0 Td
(in)Tj
1.0375 0 Td
(clinical)Tj
3.0784 0 Td
(trials)Tj
2.194 0 Td
(but)Tj
1.5534 0 Td
(get)Tj
1.4116 0 Td
(exposed)Tj
3.4413 0 Td
(to)Tj
1.0261 0 Td
(these)Tj
2.2564 0 Td
(new)Tj
1.8765 0 Td
(products)Tj
3.7531 0 Td
(once)Tj
2.1203 0 Td
(they)Tj
1.9275 0 Td
(are)Tj
1.4457 0 Td
(introduced)Tj
4.6431 0 Td
(into)Tj
-35.5462 -1.2983 Td
(the)Tj
1.4683 0 Td
(public)Tj
2.7099 0 Td
(health)Tj
2.6759 0 Td
(system)Tj
2.9367 0 Td
([)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.2642 0 Td
(4)Tj
0 g
(].)Tj
1.2586 0 Td
(When)Tj
2.6872 0 Td
(new)Tj
1.8765 0 Td
(medicinal)Tj
4.1783 0 Td
(products)Tj
3.753 0 Td
(are)Tj
1.4457 0 Td
(introduced)Tj
4.6431 0 Td
(for)Tj
1.389 0 Td
(use)Tj
1.5307 0 Td
(in)Tj
1.0374 0 Td
(the)Tj
-34.8545 -1.3039 Td
(general)Tj
3.1294 0 Td
(population,)Tj
4.8188 0 Td
(recipients)Tj
4.1216 0 Td
(are)Tj
1.4457 0 Td
(no)Tj
1.2755 0 Td
(longer)Tj
2.7836 0 Td
(critically)Tj
3.651 0 Td
(monitored)Tj
4.4901 0 Td
(for)Tj
1.389 0 Td
(AEs)Tj
1.8311 0 Td
(as)Tj
1.0148 0 Td
(in)Tj
1.0375 0 Td
(clinical)Tj
3.0784 0 Td
(trials.)Tj
-34.0665 -1.2983 Td
(Factors)Tj
3.1407 0 Td
(such)Tj
2.058 0 Td
(as)Tj
1.0148 0 Td
(sample)Tj
3.0217 0 Td
(size,)Tj
1.9105 0 Td
(participants')Tj
5.176 0 Td
(selection,)Tj
3.9402 0 Td
(follow-ups)Tj
4.456 0 Td
(and)Tj
1.7291 0 Td
(surrogate)Tj
3.9798 0 Td
(endpoints)Tj
4.2236 0 Td
(often)Tj
-34.6504 -1.2983 Td
(limit)Tj
2.1146 0 Td
(the)Tj
1.474 0 Td
(generalizability)Tj
6.2872 0 Td
(of)Tj
1.0148 0 Td
(findings)Tj
3.4923 0 Td
(from)Tj
2.2053 0 Td
(clinical)Tj
3.0727 0 Td
(trials.)Tj
2.4265 0 Td
(Moreover,)Tj
4.3936 0 Td
(due)Tj
1.7008 0 Td
(to)Tj
1.0262 0 Td
(health)Tj
2.6758 0 Td
(system)Tj
2.9367 0 Td
(chal-)Tj
-34.8205 -1.2982 Td
(lenges,)Tj
2.9139 0 Td
(when)Tj
2.4038 0 Td
(large)Tj
2.16 0 Td
(numbers)Tj
3.7757 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.474 0 Td
(population)Tj
4.5865 0 Td
(are)Tj
1.4513 0 Td
(exposed)Tj
3.4412 0 Td
(to)Tj
1.0262 0 Td
(new)Tj
1.8765 0 Td
(medicinal)Tj
4.1782 0 Td
(products,)Tj
3.9798 0 Td
(there)Tj
-34.2819 -1.3039 Td
(can)Tj
1.6157 0 Td
(be)Tj
1.1452 0 Td
(an)Tj
1.1962 0 Td
(exaggerated)Tj
4.9493 0 Td
(emergence)Tj
4.5354 0 Td
(of)Tj
1.0091 0 Td
(AEs)Tj
1.8255 0 Td
(that)Tj
1.7745 0 Td
(may)Tj
1.9218 0 Td
(undermine)Tj
4.6715 0 Td
(the)Tj
1.4627 0 Td
(usefulness)Tj
4.2803 0 Td
(of)Tj
1.0091 0 Td
(such)Tj
2.0523 0 Td
(new)Tj
1.8708 0 Td
(prod-)Tj
-35.3194 -1.2983 Td
(ucts)Tj
1.8311 0 Td
([)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(].)Tj
2.5909 0 Td
(Besides,)Tj
3.3902 0 Td
(conditions)Tj
4.473 0 Td
(and)Tj
1.7348 0 Td
(reasons)Tj
3.2258 0 Td
(for)Tj
1.3833 0 Td
(safety)Tj
2.4832 0 Td
(monitoring)Tj
4.8188 0 Td
(may)Tj
1.9276 0 Td
(change)Tj
3.0444 0 Td
(following)Tj
3.9741 0 Td
(rou-)Tj
-34.8772 -1.2983 Td
(tine)Tj
1.7574 0 Td
(use)Tj
1.5307 0 Td
(of)Tj
1.0148 0 Td
(new)Tj
1.8765 0 Td
(medicinal)Tj
4.1783 0 Td
(products)Tj
3.753 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(public)Tj
2.7099 0 Td
(health)Tj
2.6759 0 Td
(system)Tj
2.9367 0 Td
([)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.2642 0 Td
(9)Tj
0 g
(].)Tj
1.2586 0 Td
(Thus,)Tj
2.4718 0 Td
(post-licensure)Tj
-29.9336 -1.3039 Td
(surveillances)Tj
5.3064 0 Td
(are)Tj
1.4513 0 Td
(carried)Tj
3.0387 0 Td
(out)Tj
1.5534 0 Td
(to)Tj
1.0205 0 Td
(expand)Tj
3.1407 0 Td
(the)Tj
1.4684 0 Td
(evidence)Tj
3.7133 0 Td
(base)Tj
1.9446 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(characteristics)Tj
5.9074 0 Td
(of)Tj
1.0148 0 Td
(new)Tj
1.8765 0 Td
(products)Tj
-33.9191 -1.2982 Td
(for)Tj
1.3832 0 Td
(which)Tj
2.6533 0 Td
(licensure)Tj
3.8097 0 Td
(has)Tj
1.542 0 Td
(been)Tj
2.126 0 Td
(granted)Tj
3.2882 0 Td
([)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(].)Tj
-13.6062 -1.2983 Td
(Artemisinin-bas)Tj
6.5139 0 Td
(ed)Tj
1.1622 0 Td
(combination)Tj
5.3348 0 Td
(therapies)Tj
3.8381 0 Td
(\(ACTs\))Tj
3.2088 0 Td
(are)Tj
1.44 0 Td
(presently)Tj
3.8607 0 Td
(recommended)Tj
6.0265 0 Td
(for)Tj
1.3776 0 Td
(the)Tj
1.457 0 Td
(treat-)Tj
-35.4158 -1.3039 Td
(ment)Tj
2.3073 0 Td
(of)Tj
1.0148 0 Td
(uncomplicated)Tj
/F11 1 Tf
6.1852 0 Td
[()9()11()4()1()10()4()16()-9()12( )]TJ
/F7 1 Tf
4.4787 0 Td
(malaria.)Tj
3.4469 0 Td
(Currently,)Tj
4.354 0 Td
(dihydroartemisinin)Tj
8.0107 0 Td
(plus)Tj
1.8708 0 Td
(piperaquine)Tj
-31.6684 -1.2983 Td
(\(DHP\))Tj
2.9593 0 Td
(has)Tj
1.5477 0 Td
(been)Tj
2.1203 0 Td
(made)Tj
2.4265 0 Td
(an)Tj
1.2018 0 Td
(option)Tj
2.863 0 Td
(for)Tj
1.389 0 Td
(the)Tj
1.4683 0 Td
(first-line)Tj
3.6397 0 Td
(treatment)Tj
4.1385 0 Td
(of)Tj
1.0148 0 Td
(uncomplicated)Tj
6.1852 0 Td
(malaria)Tj
3.2258 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(].)Tj
-34.1799 -1.2983 Td
(The)Tj
1.7801 0 Td
(choice)Tj
2.7949 0 Td
(of)Tj
1.0148 0 Td
(any)Tj
1.6555 0 Td
(of)Tj
1.0148 0 Td
(these)Tj
2.2563 0 Td
(ACTs)Tj
2.5398 0 Td
(has)Tj
1.5421 0 Td
(been)Tj
2.1203 0 Td
(based)Tj
2.4718 0 Td
(on)Tj
1.2756 0 Td
(the)Tj
1.4683 0 Td
(level)Tj
2.0183 0 Td
(of)Tj
1.0148 0 Td
(resistance)Tj
4.1328 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(artemisinin)Tj
-31.5834 -1.3039 Td
(partner)Tj
3.1804 0 Td
(drug)Tj
2.1146 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(area)Tj
1.8822 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(].)Tj
2.075 0 Td
(The)Tj
1.7858 0 Td
(millions)Tj
3.4809 0 Td
(of)Tj
1.0148 0 Td
(doses)Tj
2.3981 0 Td
(of)Tj
1.0148 0 Td
(ACTs)Tj
2.5398 0 Td
(that)Tj
1.7802 0 Td
(are)Tj
1.4513 0 Td
(being)Tj
2.4265 0 Td
(introduced)Tj
4.6431 0 Td
(into)Tj
1.8425 0 Td
(the)Tj
-36.1358 -1.2982 Td
(health)Tj
2.6758 0 Td
(system)Tj
2.9367 0 Td
(necessitate)Tj
4.4844 0 Td
(the)Tj
1.4683 0 Td
(establishment)Tj
5.7373 0 Td
(of)Tj
1.0148 0 Td
(pharmacovigilance)Tj
7.7839 0 Td
(systems)Tj
3.2995 0 Td
(in)Tj
1.0375 0 Td
(malaria)Tj
3.2258 0 Td
(endemic)Tj
-33.664 -1.2983 Td
(countries.)Tj
4.1725 0 Td
(This)Tj
1.9843 0 Td
(is)Tj
0.8503 0 Td
(essential)Tj
3.583 0 Td
(as)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(weaknesses)Tj
4.7395 0 Td
(in)Tj
1.0318 0 Td
(existing)Tj
3.3165 0 Td
(health)Tj
2.6815 0 Td
(systems)Tj
3.2939 0 Td
(are)Tj
1.4513 0 Td
(likely)Tj
2.3527 0 Td
(to)Tj
1.0262 0 Td
(reduce)Tj
2.9196 0 Td
(the)Tj
-35.8863 -1.2983 Td
(effectiveness)Tj
5.2043 0 Td
(and)Tj
1.7291 0 Td
(safety)Tj
2.4775 0 Td
(of)Tj
1.0148 0 Td
(these)Tj
2.2564 0 Td
(new)Tj
1.8765 0 Td
(antimalarials)Tj
5.3801 0 Td
(being)Tj
2.4321 0 Td
(introduced)Tj
4.6432 0 Td
(for)Tj
1.3833 0 Td
(large-scale)Tj
4.3993 0 Td
(use.)Tj
-31.6004 -1.3039 Td
(To)Tj
1.3379 0 Td
(contribute)Tj
4.3937 0 Td
(to)Tj
1.0261 0 Td
(post-licensure)Tj
5.845 0 Td
(safety)Tj
2.4832 0 Td
(information)Tj
5.0739 0 Td
(on)Tj
1.2756 0 Td
(antimalarials,)Tj
5.6069 0 Td
(the)Tj
1.4683 0 Td
(INDEPTH-Net-)Tj
-29.7068 -1.2983 Td
(work)Tj
2.279 0 Td
(in)Tj
1.0318 0 Td
(2009)Tj
2.126 0 Td
(established)Tj
4.5977 0 Td
(an)Tj
1.2019 0 Td
(effectiveness)Tj
5.2044 0 Td
(and)Tj
1.7291 0 Td
(safety)Tj
2.4775 0 Td
(platform)Tj
3.702 0 Td
(for)Tj
1.389 0 Td
(post)Tj
1.8992 0 Td
(licensure)Tj
3.8154 0 Td
(evaluation)Tj
4.3596 0 Td
(of)Tj
-35.8126 -1.2982 Td
(newly)Tj
2.5738 0 Td
(registered)Tj
4.1556 0 Td
(antimalarials)Tj
5.3801 0 Td
(across)Tj
2.6759 0 Td
(Africa)Tj
2.6872 0 Td
([)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(].)Tj
2.0806 0 Td
(The)Tj
1.7802 0 Td
(Phase)Tj
2.5284 0 Td
(IV)Tj
1.253 0 Td
(platform)Tj
3.702 0 Td
(involved)Tj
3.651 0 Td
(eight)Tj
2.1996 0 Td
(sites)Tj
1.9333 0 Td
(in)Tj
-36.6007 -1.3039 Td
(Africa)Tj
2.6872 0 Td
(with)Tj
1.9956 0 Td
(health)Tj
2.6815 0 Td
(and)Tj
1.7291 0 Td
(demographic)Tj
5.5049 0 Td
(surveillance)Tj
4.9436 0 Td
(systems)Tj
3.2995 0 Td
(and)Tj
1.7291 0 Td
(well-established)Tj
6.548 0 Td
(pharmacovigi-)Tj
-31.1185 -1.2983 Td
(lance)Tj
2.296 0 Td
(centres)Tj
3.0671 0 Td
(for)Tj
1.3889 0 Td
(spontaneous)Tj
5.2498 0 Td
(adverse)Tj
3.2201 0 Td
(events)Tj
2.7269 0 Td
(reporting)Tj
3.9912 0 Td
([)Tj
0.83 0.64 0.02 0 k
(13)Tj
0 g
(].)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 366.4629 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Safety)Tj
3.0118 0 Td
(evaluatio)Tj
3.9189 0 Td
(n)Tj
0.7654 0 Td
(of)Tj
1.0417 0 Td
(dihydroartem)Tj
5.7331 0 Td
(isinin)Tj
2.4449 0 Td
(piperaquin)Tj
4.5709 0 Td
(e)Tj
0.7654 0 Td
(in)Tj
0.978 0 Td
(Ghana)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01745)Tj
4.089 0 Td
(03)Tj
0 g
2.0906 0 Td
(March)Tj
2.9622 0 Td
(30,)Tj
1.5874 0 Td
(2017)Tj
34.3562 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(18)Tj
ET
Q
q
0.83 0.64 0.02 0 k
1 j
1 J
0 w
83.0551 707.6409 m
185.1591 707.6409 l
h
f*
44.3339 696.6425 m
122.7969 696.6425 l
h
f*
0 g
7.9999 0 0 7.9999 36 708.7181 cm
BT
/F9 1 Tf
1 TL
-0.0062 Tc
0 0 Td
(Email)Tj
2.3456 0 Td
(address:)Tj
0.83 0.64 0.02 0 k
3.5363 0 Td
(rita.baiden@i)Tj
5.067 0 Td
(ndepth-network)Tj
6.137 0 Td
(.org)Tj
0 g
-17.0859 -1.3748 Td
(or)Tj
0.83 0.64 0.02 0 k
1.0417 0 Td
(rita_baiden)Tj
4.3087 0 Td
(@yahoo.co.u)Tj
5.0599 0 Td
(k)Tj
0 g
(].)Tj
/F8 1 Tf
-0.025 Tc
-10.4103 -2.126 Td
(Funding:)Tj
/F9 1 Tf
3.5716 0 Td
(The)Tj
1.5874 0 Td
(study)Tj
2.2678 0 Td
(was)Tj
1.7008 0 Td
(sponsored)Tj
4.1599 0 Td
(by)Tj
1.1126 0 Td
(the)Tj
-14.4001 -1.3748 Td
(INDEPTH)Tj
3.7134 0 Td
(Networ)Tj
2.6787 0 Td
(k)Tj
0.6449 0 Td
(as)Tj
1.063 0 Td
(part)Tj
1.6796 0 Td
(of)Tj
0.9425 0 Td
(the)Tj
1.3748 0 Td
(funding)Tj
3.0331 0 Td
(for)Tj
1.2543 0 Td
(the)Tj
-16.3843 -1.3748 Td
(INESS)Tj
2.5866 0 Td
(programm)Tj
3.9614 0 Td
(e)Tj
0.6449 0 Td
(by)Tj
1.1126 0 Td
(the)Tj
1.3748 0 Td
(Bill)Tj
1.3182 0 Td
(and)Tj
1.5945 0 Td
(Melinda)Tj
3.1464 0 Td
(Gates)Tj
-15.7394 -1.3748 Td
(Foundation.)Tj
4.5779 0 Td
(The)Tj
1.5875 0 Td
(funders)Tj
3.0472 0 Td
(had)Tj
1.5874 0 Td
(no)Tj
1.1622 0 Td
(role)Tj
1.6158 0 Td
(in)Tj
0.8858 0 Td
(study)Tj
-14.4638 -1.3748 Td
(design,)Tj
2.8984 0 Td
(data)Tj
1.7929 0 Td
(collection)Tj
3.7418 0 Td
(and)Tj
1.5874 0 Td
(analysis,)Tj
3.4087 0 Td
(decision)Tj
3.2953 0 Td
(to)Tj
-16.7245 -1.3748 Td
(publish,)Tj
3.1464 0 Td
(or)Tj
0.9993 0 Td
(preparation)Tj
4.4433 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
1.3677 0 Td
(manuscript.)Tj
/F8 1 Tf
-10.9063 -2.126 Td
(Competing)Tj
4.3795 0 Td
(interests)Tj
3.3307 0 Td
(:)Tj
/F9 1 Tf
0.4819 0 Td
(The)Tj
1.5875 0 Td
(authors)Tj
3.0401 0 Td
(have)Tj
1.963 0 Td
(declared)Tj
-14.7827 -1.3748 Td
(no)Tj
1.1693 0 Td
(competing)Tj
ET
endstream
endobj
38 0 obj
<>stream
endstream
endobj
39 0 obj
<>stream
endstream
endobj
40 0 obj
<>stream
endstream
endobj
41 0 obj
<>stream
endstream
endobj
42 0 obj
<>stream
endstream
endobj
43 0 obj
<>stream
endstream
endobj
44 0 obj
<>stream
endstream
endobj
45 0 obj
<>stream
endstream
endobj
46 0 obj
<>stream
endstream
endobj
47 0 obj
<>stream
endstream
endobj
48 0 obj
<>stream
endstream
endobj
49 0 obj
<>stream
endstream
endobj
50 0 obj
<>stream
BT
5.322 -13.8756 Td
(interests.)Tj
ET
Q
endstream
endobj
51 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 52 0 R/Contents 53 0 R/TrimBox[0 0 612 792]>>
endobj
52 0 obj
[54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R 60 0 R 61 0 R 62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R]
endobj
54 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref013)>>
endobj
55 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref014)>>
endobj
56 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref014)>>
endobj
57 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref014)>>
endobj
58 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref016)>>
endobj
59 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref014)>>
endobj
60 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref016)>>
endobj
61 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.g001)>>
endobj
62 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref017)>>
endobj
63 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref019)>>
endobj
64 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref017)>>
endobj
65 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref018)>>
endobj
66 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref019)>>
endobj
67 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref020)>>
endobj
68 0 obj
<>/Border[0 0 0]/Dest(Rpone.0174503.ref012)>>
endobj
69 0 obj
<>/Border[0 0 0]/A 70 0 R>>
endobj
70 0 obj
<>
endobj
53 0 obj
[71 0 R 72 0 R 73 0 R 74 0 R 75 0 R 76 0 R 77 0 R 78 0 R 79 0 R 80 0 R 81 0 R 82 0 R]
endobj
71 0 obj
<>stream
q
0.83 0.64 0.02 0 k
228.3591 628.3276 m
237.8268 628.3276 l
h
f*
223.7669 537.3354 m
233.2913 537.3354 l
h
f*
439.0299 524.2961 m
448.5543 524.2961 l
h
f*
439.3701 498.3307 m
448.8945 498.3307 l
h
f*
454.0535 498.3307 m
463.578 498.3307 l
h
f*
425.3102 485.348 m
434.8346 485.348 l
h
f*
439.9937 485.348 m
449.5181 485.348 l
h
f*
450.1417 341.915 m
469.9843 341.915 l
h
f*
551.5654 328.9323 m
561.2031 328.9323 l
h
f*
200.0126 315.9496 m
209.6504 315.9496 l
h
f*
287.7732 276.9449 m
297.411 276.9449 l
h
f*
262.0913 237.9402 m
271.7858 237.9402 l
h
f*
288.9071 198.9354 m
298.5449 198.9354 l
h
f*
203.4142 146.948 m
212.9386 146.948 l
h
f*
363.4016 81.9213 m
372.926 81.9213 l
h
f*
0 g
1 j
1 J
0 w
10 0 0 10 211.9748 707.4141 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(In)Tj
1.1111 0 Td
(Ghana,)Tj
3.1068 0 Td
(three)Tj
2.262 0 Td
(first-line)Tj
3.6397 0 Td
(artemisinin-based)Tj
7.4324 0 Td
(combination)Tj
5.3461 0 Td
(drugs)Tj
2.4718 0 Td
(are)Tj
1.4513 0 Td
(available)Tj
3.668 0 Td
(for)Tj
1.3833 0 Td
(treatment)Tj
-33.0687 -1.3039 Td
(of)Tj
1.0148 0 Td
(uncomplicated)Tj
6.1851 0 Td
(malariaArtesunate-amodiaquine)Tj
14.1334 0 Td
(\(ASAQ\))Tj
3.4866 0 Td
(and)Tj
1.7348 0 Td
(Artemether-lumefantrine)Tj
-26.5547 -1.2982 Td
(\(ALU\))Tj
2.8572 0 Td
(have)Tj
2.058 0 Td
(been)Tj
2.126 0 Td
(in)Tj
1.0318 0 Td
(the)Tj
1.474 0 Td
(public)Tj
2.7042 0 Td
(health)Tj
2.6816 0 Td
(system)Tj
2.9366 0 Td
(for)Tj
1.389 0 Td
(some)Tj
2.3301 0 Td
(time)Tj
2.0296 0 Td
(but)Tj
1.5477 0 Td
(Dihydroartemisinin-pip)Tj
9.6547 0 Td
(era-)Tj
-34.8205 -1.2983 Td
(quine)Tj
2.4944 0 Td
(\(DHP\))Tj
2.9594 0 Td
(has)Tj
1.542 0 Td
(recently)Tj
3.4129 0 Td
(been)Tj
2.1203 0 Td
(introduced)Tj
4.6431 0 Td
(and)Tj
1.7291 0 Td
(has)Tj
1.5421 0 Td
(limited)Tj
3.0727 0 Td
(pharmacovigilance)Tj
7.7839 0 Td
(safety)Tj
2.4775 0 Td
(data.)Tj
-32.5812 -1.2983 Td
(This)Tj
1.9899 0 Td
(study)Tj
2.3867 0 Td
(used)Tj
2.0636 0 Td
(the)Tj
1.4684 0 Td
(INDEPTH-Network)Tj
8.4075 0 Td
(safety-monitoring)Tj
7.4267 0 Td
(platform)Tj
3.702 0 Td
(and)Tj
1.7348 0 Td
(data)Tj
1.9105 0 Td
(from)Tj
2.2054 0 Td
(a)Tj
0.6576 0 Td
(pro-)Tj
-35.1493 -1.3039 Td
(spective)Tj
3.3902 0 Td
(phase)Tj
2.4831 0 Td
(IV)Tj
1.2529 0 Td
(study)Tj
2.3867 0 Td
(that)Tj
1.7802 0 Td
(evaluated)Tj
3.9912 0 Td
(clinical)Tj
3.0727 0 Td
(safety)Tj
2.4831 0 Td
(of)Tj
1.0148 0 Td
(fixed-dose)Tj
4.3597 0 Td
(dihydroartemisinin-piper)Tj
10.2387 0 Td
(a-)Tj
-36.4533 -1.2982 Td
(quine)Tj
2.4944 0 Td
([)Tj
0.83 0.64 0.02 0 k
(13)Tj
0 g
(].)Tj
-1.2982 -1.2983 Td
(This)Tj
1.9899 0 Td
(study)Tj
2.3867 0 Td
(assessed)Tj
3.4753 0 Td
(the)Tj
1.4683 0 Td
(safety)Tj
2.4775 0 Td
(of)Tj
1.0148 0 Td
(DHP)Tj
2.2847 0 Td
(as)Tj
1.0148 0 Td
(an)Tj
1.2019 0 Td
(additional)Tj
4.2802 0 Td
(first-line)Tj
3.6397 0 Td
(combination)Tj
5.3461 0 Td
(treatment)Tj
4.1386 0 Td
(for)Tj
-35.9147 -1.3039 Td
(acute)Tj
2.3243 0 Td
(uncomplicated)Tj
6.1852 0 Td
(malaria)Tj
3.2258 0 Td
(across)Tj
2.6759 0 Td
(three)Tj
2.2677 0 Td
(different)Tj
3.6567 0 Td
(ecological)Tj
4.1612 0 Td
(zones)Tj
2.4718 0 Td
(with)Tj
2.0012 0 Td
(health)Tj
2.6759 0 Td
(and)Tj
1.7291 0 Td
(demo-)Tj
-33.3748 -1.2983 Td
(graphic)Tj
3.2257 0 Td
(surveillance)Tj
4.9493 0 Td
(systems)Tj
3.2938 0 Td
(in)Tj
1.0375 0 Td
(Ghana.)Tj
-11.3101 -1.2983 Td
(The)Tj
1.7858 0 Td
(dihydroartemisinin)Tj
8.0106 0 Td
(\(DHA\))Tj
3.0841 0 Td
(component)Tj
4.8132 0 Td
(of)Tj
1.0148 0 Td
(DHP)Tj
2.2847 0 Td
(is)Tj
0.8504 0 Td
(very)Tj
1.9219 0 Td
(rapidly)Tj
3.0387 0 Td
(absorbed)Tj
3.8608 0 Td
(with)Tj
1.9955 0 Td
(Tmax)Tj
-33.8567 -1.3039 Td
(being)Tj
2.432 0 Td
(about)Tj
2.4945 0 Td
(12)Tj
1.6838 0 Td
(hours)Tj
2.5171 0 Td
(after)Tj
2.0353 0 Td
(single)Tj
2.5285 0 Td
(and)Tj
1.7348 0 Td
(multiple)Tj
3.5659 0 Td
(dosing.)Tj
3.1181 0 Td
(The)Tj
1.7858 0 Td
(Piperaquine)Tj
5.0627 0 Td
(\(PQ\))Tj
2.2053 0 Td
(component)Tj
4.8132 0 Td
(is)Tj
-35.977 -1.2982 Td
(highly)Tj
2.7098 0 Td
(lipophilic,)Tj
4.2293 0 Td
(slowly)Tj
2.7212 0 Td
(absorbed)Tj
3.8551 0 Td
(and)Tj
1.7292 0 Td
(has)Tj
1.5477 0 Td
(a)Tj
0.6519 0 Td
(Tmax)Tj
2.5512 0 Td
(of)Tj
1.0148 0 Td
(about)Tj
2.4945 0 Td
(45)Tj
1.6837 0 Td
(hours)Tj
2.5172 0 Td
(after)Tj
2.0353 0 Td
(single)Tj
2.5284 0 Td
(and)Tj
1.7348 0 Td
(repeated)Tj
-34.0041 -1.2983 Td
(dose)Tj
2.0352 0 Td
([)Tj
0.83 0.64 0.02 0 k
(14)Tj
0 g
(].)Tj
2.0806 0 Td
(Piperaquine)Tj
5.0627 0 Td
(can)Tj
1.627 0 Td
(accumulate)Tj
4.7792 0 Td
(in)Tj
1.0375 0 Td
(patients')Tj
3.583 0 Td
(plasma)Tj
3.033 0 Td
(after)Tj
2.0296 0 Td
(multiple)Tj
3.5716 0 Td
(doses)Tj
2.3981 0 Td
(with)Tj
1.9956 0 Td
(an)Tj
1.2019 0 Td
(accu-)Tj
-34.435 -1.3039 Td
(mulation)Tj
3.8664 0 Td
(factor)Tj
2.5455 0 Td
(of)Tj
1.0148 0 Td
(around)Tj
3.1351 0 Td
(three)Tj
2.262 0 Td
(due)Tj
1.7008 0 Td
(to)Tj
1.0261 0 Td
(its)Tj
1.1452 0 Td
(slow)Tj
2.0182 0 Td
(elimination)Tj
4.8473 0 Td
([)Tj
0.83 0.64 0.02 0 k
(14)Tj
0 g
(].)Tj
2.0749 0 Td
(The)Tj
1.7858 0 Td
(increase)Tj
3.4696 0 Td
(in)Tj
1.0375 0 Td
(PQ)Tj
1.525 0 Td
(concen-)Tj
-33.4542 -1.2983 Td
(tration)Tj
2.9423 0 Td
(is)Tj
0.8504 0 Td
(more)Tj
2.3414 0 Td
(pronounced)Tj
5.1193 0 Td
(when)Tj
2.4038 0 Td
(administered)Tj
5.4935 0 Td
(with)Tj
1.9956 0 Td
(a)Tj
0.6519 0 Td
(high)Tj
2.0069 0 Td
(fat)Tj
1.2416 0 Td
(or)Tj
1.0998 0 Td
(high)Tj
2.007 0 Td
(calorie)Tj
2.8913 0 Td
(meal)Tj
2.143 0 Td
(and)Tj
1.7348 0 Td
(the)Tj
-34.9226 -1.2982 Td
(effect)Tj
2.364 0 Td
(is)Tj
0.8447 0 Td
(of)Tj
1.0148 0 Td
(clinical)Tj
3.0784 0 Td
(relevance)Tj
3.9685 0 Td
(due)Tj
1.7008 0 Td
(to)Tj
1.0261 0 Td
(prolonged)Tj
4.3313 0 Td
(QTc)Tj
2.0013 0 Td
(interval)Tj
3.2655 0 Td
([)Tj
0.83 0.64 0.02 0 k
(14)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(16)Tj
0 g
(].)Tj
-22.3992 -1.2983 Td
(In)Tj
1.1111 0 Td
(view)Tj
2.0523 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(concerns)Tj
3.8268 0 Td
(about)Tj
2.4944 0 Td
(cardiotoxicity)Tj
5.7317 0 Td
(of)Tj
1.0148 0 Td
(DHP)Tj
2.279 0 Td
([)Tj
0.83 0.64 0.02 0 k
(14)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(16)Tj
0 g
(],)Tj
3.549 0 Td
(this)Tj
1.6724 0 Td
(study)Tj
2.3867 0 Td
(investigated)Tj
4.9947 0 Td
(the)Tj
-34.7922 -1.3039 Td
(safety)Tj
2.4774 0 Td
(of)Tj
1.0148 0 Td
(DHP)Tj
2.2847 0 Td
(when)Tj
2.4038 0 Td
(used)Tj
2.0579 0 Td
(under)Tj
2.6192 0 Td
(normal)Tj
3.1464 0 Td
(conditions)Tj
4.4788 0 Td
(in)Tj
1.0318 0 Td
(patients)Tj
3.3675 0 Td
(with)Tj
2.0012 0 Td
(acute)Tj
2.3244 0 Td
(signs)Tj
2.2224 0 Td
(and)Tj
1.7348 0 Td
(symptoms)Tj
-33.1651 -1.2983 Td
(of)Tj
1.0148 0 Td
(uncomplicated)Tj
6.1851 0 Td
(malaria.)Tj
3.4469 0 Td
(It)Tj
0.8617 0 Td
(particularly)Tj
4.8132 0 Td
(assessed)Tj
3.4696 0 Td
(the)Tj
1.4683 0 Td
(relationship)Tj
4.989 0 Td
(between)Tj
3.5319 0 Td
(occurrence)Tj
4.6602 0 Td
(of)Tj
-34.4407 -1.2983 Td
(adverse)Tj
3.2144 0 Td
(events,)Tj
2.9537 0 Td
(study)Tj
2.3924 0 Td
(completion)Tj
4.7792 0 Td
(rate,)Tj
1.9672 0 Td
(participant)Tj
4.5978 0 Td
(characteristics)Tj
5.9074 0 Td
(and)Tj
1.7291 0 Td
(concomitant)Tj
5.2951 0 Td
(medication,)Tj
-32.8363 -1.3039 Td
(and)Tj
1.7291 0 Td
(changes)Tj
3.4015 0 Td
(in)Tj
1.0375 0 Td
(QTc)Tj
2.0012 0 Td
(intervals)Tj
3.6227 0 Td
(in)Tj
1.0375 0 Td
(a)Tj
0.6519 0 Td
(subgroup)Tj
4.0082 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(participants.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 391.011 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Materials)Tj
4.5071 0 Td
(and)Tj
1.989 0 Td
(methods)Tj
/F0 1 Tf
-6.4961 -1.5023 Td
(Study)Tj
2.7543 0 Td
(settings)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 355.9748 cm
BT
/F7 1 Tf
1 TL
0.003 Tc
0 0 Td
(The)Tj
1.8028 0 Td
(study)Tj
2.4264 0 Td
(was)Tj
1.7178 0 Td
(conducted)Tj
4.49 0 Td
(across)Tj
2.7213 0 Td
(Ghana)Tj
2.914 0 Td
(in)Tj
1.0488 0 Td
(three)Tj
2.3017 0 Td
(health)Tj
2.7156 0 Td
(research)Tj
3.6113 0 Td
(centres)Tj
3.1238 0 Td
(where)Tj
2.6815 0 Td
(there)Tj
2.3017 0 Td
(are)Tj
1.4684 0 Td
(on-)Tj
-35.3251 -1.2982 Td
(going)Tj
2.5058 0 Td
(Health)Tj
2.9593 0 Td
(and)Tj
1.7518 0 Td
(Demographic)Tj
5.7883 0 Td
(Surveillance)Tj
5.1477 0 Td
(Systems)Tj
3.4639 0 Td
(\(HDSS\))Tj
0.83 0.64 0.02 0 k
3.3959 0 Td
(Fig)Tj
1.5024 0 Td
(1)Tj
0 g
(.)Tj
0.9354 0 Td
(The)Tj
1.8028 0 Td
(epidemiology)Tj
5.7316 0 Td
(of)Tj
-34.9849 -1.2983 Td
(malaria)Tj
3.2711 0 Td
(and)Tj
1.7518 0 Td
(the)Tj
1.491 0 Td
(demographic)Tj
5.5842 0 Td
(features)Tj
3.4016 0 Td
(of)Tj
1.0318 0 Td
(the)Tj
1.4853 0 Td
(three)Tj
2.3018 0 Td
(sites)Tj
1.9672 0 Td
(have)Tj
2.0863 0 Td
(been)Tj
2.1486 0 Td
(described)Tj
4.1159 0 Td
(elsewhere)Tj
4.1669 0 Td
([)Tj
0.83 0.64 0.02 0 k
(17)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
-34.8035 -1.2982 Td
(19)Tj
0 g
(].)Tj
1.7631 0 Td
(Briefly,)Tj
3.1351 0 Td
(the)Tj
1.4853 0 Td
(Dodowa)Tj
3.6624 0 Td
(HDSS)Tj
2.6985 0 Td
(is)Tj
0.8674 0 Td
(located)Tj
3.1238 0 Td
(in)Tj
1.0545 0 Td
(South-eastern)Tj
5.8563 0 Td
(Ghana)Tj
2.914 0 Td
(covering)Tj
3.7361 0 Td
(two)Tj
1.7291 0 Td
(peri-urban)Tj
-32.0256 -1.304 Td
(districts)Tj
3.4582 0 Td
(of)Tj
1.0261 0 Td
(Shai-Osudoku)Tj
6.0548 0 Td
(and)Tj
1.7518 0 Td
(Ningo-Prampram)Tj
7.5174 0 Td
(in)Tj
1.0488 0 Td
(the)Tj
1.4911 0 Td
(Greater)Tj
3.3051 0 Td
(Accra)Tj
2.5966 0 Td
(region.)Tj
3.0727 0 Td
(It)Tj
0.8731 0 Td
(has)Tj
1.5647 0 Td
(a)Tj
0.6633 0 Td
(com-)Tj
-34.4237 -1.2982 Td
(bined)Tj
2.5284 0 Td
(population)Tj
4.6602 0 Td
(of)Tj
1.0261 0 Td
(about)Tj
2.5285 0 Td
(112)Tj
1.6724 0 Td
(000,)Tj
1.8992 0 Td
(surface)Tj
3.0954 0 Td
(area)Tj
1.9106 0 Td
(of)Tj
1.0318 0 Td
(1528.9)Tj
2.863 0 Td
(km)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 445.4929 295.4267 cm
BT
/F7 1 Tf
1 TL
0.004 Tc
0 0 Td
(2)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 451.3322 291.0047 cm
BT
/F7 1 Tf
1 TL
0.003 Tc
0 0 Td
(and)Tj
1.7517 0 Td
(characterized)Tj
5.6466 0 Td
(by)Tj
1.1962 0 Td
(coastal)Tj
-33.7263 -1.2982 Td
(savannah)Tj
4.0195 0 Td
(vegetation)Tj
4.4107 0 Td
([)Tj
0.83 0.64 0.02 0 k
(17)Tj
0 g
(].)Tj
2.109 0 Td
(The)Tj
1.8028 0 Td
(Kintampo)Tj
4.3427 0 Td
(HDSS)Tj
2.7042 0 Td
(is)Tj
0.8617 0 Td
(located)Tj
3.1295 0 Td
(in)Tj
1.0488 0 Td
(the)Tj
1.4909 0 Td
(forest-)Tj
2.8686 0 Td
(savannah)Tj
4.0195 0 Td
(transitional)Tj
-32.8079 -1.3039 Td
(zone)Tj
2.1373 0 Td
(in)Tj
1.0489 0 Td
(the)Tj
1.491 0 Td
(middle)Tj
3.0784 0 Td
(belt)Tj
1.7178 0 Td
(of)Tj
1.0318 0 Td
(Ghana.)Tj
3.1464 0 Td
(The)Tj
1.8028 0 Td
(area)Tj
1.9106 0 Td
(is)Tj
0.8617 0 Td
(rural)Tj
2.2053 0 Td
(comprising)Tj
4.8415 0 Td
(the)Tj
1.491 0 Td
(Kintampo)Tj
4.337 0 Td
(North)Tj
2.6985 0 Td
(and)Tj
-33.8 -1.2983 Td
(South)Tj
2.5909 0 Td
(districts)Tj
3.4582 0 Td
(with)Tj
2.024 0 Td
(about)Tj
2.5284 0 Td
(7,162)Tj
2.3868 0 Td
(km)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 343.1622 256.422 cm
BT
/F7 1 Tf
1 TL
0.004 Tc
0 0 Td
(2)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 349.0015 252 cm
BT
/F7 1 Tf
1 TL
0.003 Tc
0 0 Td
(surface)Tj
3.0954 0 Td
(area)Tj
1.9105 0 Td
(and)Tj
1.7518 0 Td
(a)Tj
0.6633 0 Td
(combined)Tj
4.2973 0 Td
(resident)Tj
3.4979 0 Td
(population)Tj
4.6602 0 Td
(of)Tj
-34.7752 -1.2982 Td
(about)Tj
2.5285 0 Td
(143)Tj
1.6668 0 Td
(000)Tj
1.6668 0 Td
([)Tj
0.83 0.64 0.02 0 k
(18)Tj
0 g
(].)Tj
2.1146 0 Td
(The)Tj
1.8028 0 Td
(Navrongo)Tj
4.2973 0 Td
(HDSS)Tj
2.7041 0 Td
(covers)Tj
2.8007 0 Td
(two)Tj
1.7347 0 Td
(districtsthe)Tj
5.658 0 Td
(Kassena-Nankana)Tj
7.5457 0 Td
(Munic-)Tj
-34.52 -1.3039 Td
(ipal)Tj
1.7122 0 Td
(and)Tj
1.7518 0 Td
(the)Tj
1.491 0 Td
(Kassena)Tj
3.5036 0 Td
(Nankana)Tj
3.9004 0 Td
(West)Tj
2.2961 0 Td
(districts)Tj
3.4581 0 Td
(of)Tj
1.0262 0 Td
(northeastern)Tj
5.4198 0 Td
(Ghana.)Tj
3.1464 0 Td
(The)Tj
1.8028 0 Td
(districts)Tj
3.4583 0 Td
(are)Tj
1.474 0 Td
(pre-)Tj
-34.4407 -1.2983 Td
(dominantly)Tj
4.938 0 Td
(rural)Tj
2.211 0 Td
(with)Tj
2.0239 0 Td
(an)Tj
1.2132 0 Td
(area)Tj
1.9106 0 Td
(of)Tj
1.0318 0 Td
(1,685)Tj
2.381 0 Td
(km)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 370.4314 217.4173 cm
BT
/F7 1 Tf
1 TL
0.004 Tc
0 0 Td
(2)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 374.0598 212.9952 cm
BT
/F7 1 Tf
1 TL
0.003 Tc
0 0 Td
(,)Tj
0.4535 0 Td
(population)Tj
4.6601 0 Td
(of)Tj
1.0262 0 Td
(about)Tj
2.5284 0 Td
(156)Tj
1.6668 0 Td
(000)Tj
1.6724 0 Td
(and)Tj
1.7462 0 Td
(Guinea)Tj
-31.1582 -1.2982 Td
(Savannah)Tj
4.1329 0 Td
(vegetation)Tj
4.4107 0 Td
([)Tj
0.83 0.64 0.02 0 k
(19)Tj
0 g
(].)Tj
-0.004 Tc
-7.3474 -1.3039 Td
(Malaria)Tj
3.2996 0 Td
(is)Tj
0.8503 0 Td
(endemic)Tj
3.651 0 Td
(in)Tj
1.0375 0 Td
(all)Tj
1.1452 0 Td
(the)Tj
1.474 0 Td
(three)Tj
2.262 0 Td
(study)Tj
2.3868 0 Td
(sites)Tj
1.9331 0 Td
(with)Tj
/F11 1 Tf
1.9956 0 Td
[(\n)30()6()11()10(\r)6()15()4()8()]TJ
4.2009 0 Td
[()2()16( )17()11()4()6()]TJ
3.515 0 Td
[()]TJ
/F7 1 Tf
(.)Tj
/F11 1 Tf
[()]TJ
/F7 1 Tf
1.0148 0 Td
(and)Tj
/F11 1 Tf
1.7291 0 Td
[()4()4()10( )6()4()12()12()12( )]TJ
-31.6911 -1.2983 Td
[()9()11()4()1()10()4()16()-9()12( )]TJ
/F7 1 Tf
4.4731 0 Td
(being)Tj
2.4321 0 Td
(the)Tj
1.4683 0 Td
(most)Tj
2.2054 0 Td
(predominant)Tj
5.4878 0 Td
(malaria)Tj
3.2257 0 Td
(vector)Tj
2.6986 0 Td
(and)Tj
1.7291 0 Td
(parasite)Tj
3.3279 0 Td
(respectively.)Tj
5.108 0 Td
(Recent)Tj
2.9593 0 Td
(para-)Tj
-35.1153 -1.2983 Td
(site)Tj
1.5704 0 Td
(prevalence)Tj
4.4844 0 Td
(estimates)Tj
3.9061 0 Td
(ranged)Tj
2.9934 0 Td
(from)Tj
2.2053 0 Td
(5%)Tj
1.4514 0 Td
(along)Tj
2.4206 0 Td
(the)Tj
1.4684 0 Td
(coast)Tj
2.245 0 Td
(to)Tj
1.0261 0 Td
(about)Tj
2.4945 0 Td
(40%)Tj
1.9275 0 Td
(in)Tj
1.0318 0 Td
(northern)Tj
3.8211 0 Td
(Ghana)Tj
-33.046 -1.2982 Td
([)Tj
0.83 0.64 0.02 0 k
(20)Tj
0 g
(].)Tj
2.075 0 Td
(The)Tj
1.7801 0 Td
(Ghana)Tj
2.88 0 Td
(national)Tj
3.5036 0 Td
(malaria)Tj
3.2315 0 Td
(control)Tj
3.1181 0 Td
(programme)Tj
4.9491 0 Td
(in)Tj
1.0375 0 Td
(2013)Tj
2.1203 0 Td
(estimated)Tj
4.0762 0 Td
(11.3)Tj
1.8709 0 Td
(million)Tj
3.1237 0 Td
(malaria)Tj
-33.766 -1.3039 Td
(cases,)Tj
2.4492 0 Td
(approximately)Tj
5.9753 0 Td
(43%)Tj
1.9276 0 Td
(of)Tj
1.0148 0 Td
(all)Tj
1.1452 0 Td
(out)Tj
1.5534 0 Td
(patient)Tj
3.0047 0 Td
(department)Tj
4.8868 0 Td
(attendances)Tj
4.9379 0 Td
(and)Tj
1.7291 0 Td
(417)Tj
1.6498 0 Td
(cases)Tj
2.2223 0 Td
(per)Tj
1.5307 0 Td
(1,000)Tj
-34.0268 -1.2983 Td
(populations.)Tj
5.1647 0 Td
(The)Tj
1.7745 0 Td
(first)Tj
1.7915 0 Td
(line)Tj
1.6951 0 Td
(treatments)Tj
4.49 0 Td
(for)Tj
1.372 0 Td
(uncomplicated)Tj
6.1737 0 Td
(malaria)Tj
3.2202 0 Td
(in)Tj
1.0261 0 Td
(Ghana)Tj
2.8686 0 Td
(are)Tj
1.4344 0 Td
(artesunate-amo-)Tj
-31.0108 -1.2983 Td
(diaquine,)Tj
3.9458 0 Td
(artemether-lumefantr)Tj
8.7023 0 Td
(ine)Tj
1.457 0 Td
(and)Tj
1.7292 0 Td
(recently)Tj
3.4128 0 Td
(dihydroartemisinin-piperaquine.)Tj
13.3851 0 Td
(All)Tj
1.4003 0 Td
(the)Tj
1.4683 0 Td
(sites)Tj
-35.5008 -1.3039 Td
(were)Tj
2.1203 0 Td
(part)Tj
1.8425 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(INDEPTH-Network)Tj
8.4075 0 Td
(Phase)Tj
2.5228 0 Td
(IV)Tj
1.2585 0 Td
(platform)Tj
3.702 0 Td
(set)Tj
1.3039 0 Td
(up)Tj
1.2643 0 Td
(to)Tj
1.0261 0 Td
(evaluate)Tj
3.4583 0 Td
(the)Tj
1.4683 0 Td
(safety)Tj
2.4831 0 Td
(and)Tj
1.7292 0 Td
(effec-)Tj
-35.07 -1.2983 Td
(tiveness)Tj
3.3562 0 Td
(of)Tj
1.0148 0 Td
(antimalarial)Tj
5.023 0 Td
(drug)Tj
2.109 0 Td
(treatments)Tj
4.4957 0 Td
([)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(].)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 366.4629 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Safety)Tj
3.0118 0 Td
(evaluatio)Tj
3.9189 0 Td
(n)Tj
0.7654 0 Td
(of)Tj
1.0417 0 Td
(dihydroartem)Tj
5.7331 0 Td
(isinin)Tj
2.4449 0 Td
(piperaquin)Tj
4.5709 0 Td
(e)Tj
0.7654 0 Td
(in)Tj
0.978 0 Td
(Ghana)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01745)Tj
4.089 0 Td
(03)Tj
0 g
2.0906 0 Td
(March)Tj
2.9622 0 Td
(30,)Tj
1.5874 0 Td
(2017)Tj
34.3562 0 Td
(3)Tj
0.7654 0 Td
(/)Tj
ET
endstream
endobj
72 0 obj
<>stream
endstream
endobj
73 0 obj
<>stream
endstream
endobj
74 0 obj
<>stream
endstream
endobj
75 0 obj
<>stream
endstream
endobj
76 0 obj
<>stream
endstream
endobj
77 0 obj
<>stream
endstream
endobj
78 0 obj
<>stream
endstream
endobj
79 0 obj
<>stream
endstream
endobj
80 0 obj
<>stream
endstream
endobj
81 0 obj
<>stream
endstream
endobj
82 0 obj
<>stream
BT
66.402 0 Td
(18)Tj
ET
Q
endstream
endobj
83 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 86 0 R/Contents 87 0 R/TrimBox[0 0 612 792]>>
endobj
85 0 obj
<>stream
JFIF C
$, !$4.763.22:ASF:=N>22HbINVX]^]8EfmeZlS[]Y C**Y;2;YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY ("
} !1AQa"q2#BR$3br
%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz
w !1AQaq"2B #3Rbr
$4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ? (
(
(
(
xmEv=&ȳ פ
_wq k |?W3_hM1qC]' j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ T
k |?Q ' M ß
_' G j ? w& wq A9 @ UC\vkji%GF\႒&:};Q-~c0w G#Ve " +((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((M "Ϋ ^ &+/,/hi ]W_\??
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
/:zK Ԭ ȳ פ?_* һ
Ȩ? J( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ȳ פ J7:zK g "g!E4 +(((((hM"{pJ" }A^PW$y:_lN}Srz'
RP[}d/Bф>pzЊC&X̥UTI4ފZWI#][u0Zy :߈ZwC:HLgPvz*V3E
b=y\8}A?$P$l{.KEx &^(z,G&Bz ?zEV2iꧡKؽE e 2˴~I n)+'uauk)$1ۗwc~MXQE!K^#oM/d=>ElZUpz;( nڊncyhܹ3ny9 fvW:J6ލPޘ6ϴ?ww_¸v q3qڥܛQE!Q@W+ d-1Bh#+R*$vHMohZ;zZv q3q
aEPEPEPEPEPEPEPEPEPEPY~% gU IZ_u_ @4EA ]Wa\/w] QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE QE ou_ A5Y~&